1

# Post-diagnosis dietary factors and survival after invasive breast cancer

Jeannette M. Beasley<sup>1</sup>, Polly A. Newcomb<sup>1,2</sup>, Amy Trentham-Dietz<sup>2,3</sup>, John M. Hampton<sup>2</sup>, Andrew J. Bersch<sup>2</sup>, Michael N. Passarelli<sup>1</sup>, Crystal N. Holick<sup>1,4</sup>, Linda Titus-Ernstoff<sup>5</sup>, Kathleen M. Egan<sup>6</sup>, Michelle D. Holmes<sup>7</sup>, Walter C. Willett<sup>7</sup>

- 1. Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109
- 2. University of Wisconsin Carbone Cancer Center, Madison, WI 53792
- 3. Department of Population Health Sciences, University of Wisconsin, Madison, WI 53726
- 4. Research Operations, Safety and Epidemiology, HealthCore, Inc., Wilmington, DE 19801
- 5. Norris Cotton Cancer Center, Dartmouth Medical School, Lebanon, NH 03755
- Risk Assessment, Detection & Intervention Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612
- 7. Channing Laboratory, Harvard Medical School, Brigham & Women's Hospital, Boston, MA 02115

### Corresponding Author:

Polly A. Newcomb, PhD, MPH

Fred Hutchinson Cancer Research Center, M4-B402

1100 Fairview Ave. N.

Seattle, WA 98109-1024

Phone: 206-667-3476

Fax: 206-667-7850

Email: pnewcomb@fhcrc.org

Keywords: breast cancer; survival; post-diagnosis diet

Running title: Post-diagnosis diet and breast cancer survival

Abstract word count: 252; Manuscript word count: 3,510 including references, excluding tables

Number of tables: 4; Number of figures: 0

Conflicts of interest: none declared

### **ABSTRACT**

Little is known about the effects of diet after breast cancer diagnosis on survival. We prospectively examined the relation between post-diagnosis dietary factors and breast cancer and all-cause survival in women with a history of invasive breast cancer diagnosed between 1987 and 1999 (at ages 20-79 years). Diet after breast cancer diagnosis was measured using a 126-item food frequency questionnaire. Among 4,441 women without a history of breast cancer recurrence prior to completing the questionnaire, 137 subsequently died from breast cancer within 7 years of enrollment. Hazard ratios (HR) and 95% confidence intervals (CI) were estimated for intake of macronutrients as well as selected micronutrients and food groups from Cox proportional hazards regression models. After adjustment for factors at diagnosis (age, state of residence, menopausal status, smoking, breast cancer stage, alcohol, history of hormone replacement therapy), interval between diagnosis and diet assessment, and at followup (energy intake, breast cancer treatment, body mass index, and physical activity), women in the highest compared to lowest quintile of intake of saturated fat and trans fat had a significantly higher risk of dying from any cause (HR = 1.41, 95% CI = 1.06 to 1.87, P-trend = 0.03) for saturated fat; (HR = 1.78, 95% CI = 1.35 to 2.32, P-trend = 0.01) for trans fat intake. Associations were similar, though did not achieve statistical significance, for breast cancer survival. This study suggests that lower intake of saturated and trans fat in the post-diagnosis diet is associated with improved survival after breast diagnosis. cancer

### **ABBREVIATIONS**

BMI body mass index

CI confidence interval

CWLS Collaborative Women's Longevity Study

FFQ food frequency questionnaire

HR hazard ratio

MET metabolic equivalent of task

NHS Nurses' Health Study

WHEL Women's Healthy Eating and Living

WINS Women's Intervention Nutrition Study

### INTRODUCTION

With a growing number of breast cancer survivors, there is tremendous interest in establishing whether changes in lifestyle influence breast cancer outcome. Diet after the diagnosis of breast cancer has been investigated in both observational studies and randomized controlled trials [1-5]. The Women's Intervention Nutrition Study (WINS) reported a 24% (95% confidence interval (CI) = 2% to 40%) reduction in breast cancer relapse (local, regional, or distal recurrence or contralateral breast cancer) in the low fat dietary intervention (target = 15% kcal from fat) compared with the control group after a median follow-up of 5 years, but there was no effect on overall survival (hazard ratio (HR) = 0.89, 95% CI = 0.65 to 1.21) [2]. The interpretation of findings is complicated by the substantial weight loss in the intervention group. The Women's Healthy Eating and Living (WHEL) randomized trial demonstrated no effect of a low fat dietary intervention (target = 15-20% kcal from fat) on breast cancer relapse (recurrence or new primary) or survival after a mean follow-up of 7.3 years [3].

Observational studies may help to inform the research question of diet after diagnosis by providing an opportunity to examine a wider variety of dietary factors and range of exposures. For example, both the WINS and WHEL interventions focused on reduction of total fat, rather than specific types of fat. In contrast to the general population of breast cancer survivors in the US, WHEL participants already consumed a diet that met many of the intervention goals at baseline, eating on average 7.3 servings of fruits and vegetables per day [6]. Observational studies may provide a more representative sample of women consuming diets that reflect typical diets in the US [1]. We investigated the association between post-diagnosis diet and breast cancer survival and overall survival in the Collaborative Women's Longevity Study (CWLS), a large multi-center prospective cohort designed to examine the contribution of lifestyle to survival among women with breast cancer.

### **METHODS**

## Participants and Study Description

Women of ages 20-79 years at breast cancer diagnosis were recruited into the CWLS after their participation in consecutive population-based case-control studies of breast cancer conducted in Wisconsin, Massachusetts (excluding metropolitan Boston), and New Hampshire between 1988 and 2001. Details of both the case-control studies and the CWLS are provided elsewhere [7-9]. The purpose of the CWLS was to evaluate associations between post-diagnosis lifestyle factors and survival. Briefly, 5,791 cases from the parent case-control studies participated in the CWLS study by completing a mailed questionnaire from 1998-2001. The CWLS questionnaire assessed post-diagnosis behaviors, including diet and physical activity, as well as breast cancer events and treatment.

### **Exposure and Outcome Assessment**

Usual diet over the past year was assessed using a validated 126-item food frequency questionnaire (FFQ) [10]. Macronutrients, expressed as a percentage of total energy intake,

and select micronutrients were computed from FFQ data. Participants were categorized into quintiles based on individual macronutrient, vitamin A, carotenoid, fiber, calcium, and vitamin D intake including intake from both diet and supplements. Analyses were repeated restricting to micronutrients from diet alone to consider whether source of intake was affecting associations.

Number of servings of meat, dairy, fruit, and vegetable intake was summed based on questionnaire items and grouped into quartiles. Meat and dairy food groups were also grouped based on their fat content (<30% vs. ≥30% kcal from fat), and meat was examined separately by type (poultry, fish, beef, and processed).

Overall, 42% of women completed the CWLS questionnaire within 5 years of diagnosis of breast cancer (range: 1-16 years). We assessed all breast cancer cases for vital status regardless of whether they completed the CWLS questionnaire. We linked cases to the National Death Index records to obtain date and underlying cause of death, which has been shown to be a reliable source [11].

# Study Population

For this analysis, women were excluded if: energy intake was <500 or >5000 kcal per day as measured by the FFQ (N = 20), disease or treatment interfered with diet (N = 128), there was breast cancer metastases (N = 34) or unknown disease stage at diagnosis (N = 615), or women recorded any recurrence of breast cancer before entry into the CWLS (N = 553). Following these exclusions, the final analytic cohort comprised of 4,441 women.

### Statistical Analysis

Person-time of follow-up was calculated from the date of return of the CWLS questionnaire (1998-2001) until the date of death or December 31, 2005. Cox proportional hazards regression was used to estimate HRs and 95% CI for all-cause and breast cancer survival according to nutrient and food intake and to adjust for covariates potentially associated with both diet and mortality. Fully-adjusted models included *factors at diagnosis*: age (four categories), state of residence, menopausal status (pre/post), smoking (never, former, current),

breast cancer stage (local or regional), alcohol (quintiles), history of hormone replacement therapy (never, former, current), and *factors at follow-up*: energy intake (continuous), breast cancer treatment (surgery, radiation, chemotherapy, tamoxifen), body mass index (BMI, < 24.9, 25.0-29.9, ≥30.0 kg/m²), and physical activity metabolic equivalents (MET-h/wk, quartiles). Models further adjusted for years between diagnosis and diet assessment, and were energy-adjusted using the multivariate nutrient density method for macronutrients and the standard approach for micronutrients [12]. Tests of linear trend were conducted by including the median intake for each exposure category as an ordinal term in models.

Analyses were repeated restricting the outcome to each of the top three causes of death: breast cancer, cardiovascular disease, and cancer at any site. To evaluate the possibility that severity of illness affected diet, we performed a subgroup analysis excluding: women who died within two years of completing the CWLS survey, women reporting recent unintentional weight loss (5% or more of body weight), and women without a mammogram or physician breast exam after their diagnosis. All reported *P*-values are two-tailed without consideration of multiple comparisons; *P*-values < 0.05 were considered statistically significant. Analyses were conducted using SAS version 9.1 (SAS Institute Inc., Cary, NC).

### **RESULTS**

The majority of women were white (99%) and postmenopausal at diagnosis (76%). After a mean follow-up of 5.5 (SD 1.1) years after returning the questionnaire, we documented 525 deaths, of which 26.1% were attributed to breast cancer. The other most common causes of death were cardiovascular disease (25.1%) and cancer at other sites (24.6%). The proportion of women dying was higher among women who were older, had more advanced disease, were postmenopausal at diagnosis, and had a history of smoking, whereas the proportion dying was lower among those who reported being more physically active (**Table 1**). In contrast to all-cause survival, breast cancer survival was higher among younger women.

While all associations between energy and macronutrients with breast cancer survival were null, some associations with all-cause survival were statistically significant (**Table 2**). Total fat intake was not associated with all-cause or breast cancer survival, but type of fat intake did appear to influence risk of death from any cause. Women with a median intake of 13% of calories from saturated fat had a 41% increased risk of death from any cause compared to women consuming a median of 7% calories from saturated fat (HR = 1.41, 95% CI = 1.06 to 1.87, *P*-trend = 0.03). Furthermore, those in the upper quintile of trans fat intake had a 78% increased risk of all-cause survival compared to those in the lowest quintile (HR = 1.78, 95% CI = 1.35 to 2.32, *P*-trend = 0.01). Though similar HRs for saturated and trans fat intake were observed for cause-specific survival (breast cancer, any cancer, cardiovascular disease), the associations were not statistically significant. No consistent associations were observed between all-cause or breast cancer survival and monounsaturated or polyunsaturated fat intake.

Carbohydrate and protein intakes were not associated with all-cause or breast cancer survival. We observed a trend toward lower risk of death from any cause with higher alcohol consumption (P-trend = 0.01), but this trend was not present for breast cancer survival (P-trend = 0.50). When restricting analyses to deaths related to cardiovascular disease (N = 123), there was a non-statistically significant (P-trend = 0.11) positive association between trans fat intake and survival, and inverse associations with polyunsaturated fat (P-trend = 0.05) and alcohol intakes (P-trend = 0.14) with cardiovascular disease survival (data not shown).

Sensitivity analyses were conducted restricting attention to women who survived at least two years after completing the CWLS survey, reported no recent unintentional weight loss (5% or more of body weight), and had a mammogram or physician breast exam after their diagnosis (N = 3,977). For all-cause survival, the associations with saturated fat (HR for highest vs. lowest quintile = 1.52, 95% CI = 1.07-2.16, P-trend = 0.09) and trans fat (HR = 1.56, 95% CI = 1.11-2.17, P-trend = 0.01) were robust, but the association with alcohol was null (HR = 0.99, 95% CI = 0.72-1.36, P-trend = 0.51).

There was a non-statistically significant trend towards decreased risk of death from breast cancer with higher calcium and a positive association with lycopene intake; no association was observed for the other selected micronutrients (**Table 3**). Associations between diet and all-cause and breast cancer survival were similar to those presented after excluding supplements. There was a non-significant inverse trend (*P*-trend = 0.09) between calcium intake and breast cancer death, but there were no other associations between consumption of the selected micronutrients and breast cancer survival (data not shown).

Meat and dairy are two of the largest contributors to saturated fat intake. No significant associations were observed between all-cause and breast cancer survival and intakes of meat and dairy products (**Table 4**). We also examined meat and dairy servings/day according to fat intake (<30% vs. ≥30% kcal from fat) as well as type of meat (poultry, fish, beef, and processed), but there were no associations for all-cause or breast cancer specific survival. Because fruits and vegetables, particularly cruciferous vegetables, may be associated with a reduced risk of cancer, we also examined the relation between produce intake and all-cause and breast cancer survival; no association was observed.

### DISCUSSION

In this large cohort of breast cancer survivors, post-diagnosis diets high in saturated and trans fat were associated with decreased all-cause survival. Though there were suggestive dietary associations for breast cancer survival, none were statistically significant.

Women who consumed the highest quartile of saturated fat (median of 13% kcal) had a 41% statistically significant higher risk of all-cause survival compared to women in the lowest quartile, who consumed a median of 7% calories from saturated fat (P-trend = 0.03). Doubling percentage of energy from trans fat was associated with a 78% statistically significantly greater risk of death (P-trend = 0.01).

A recent report from the Center for Disease Control and Prevention indicated that saturated fat intake as a percentage of energy intake decreased between 1971-2000 among US women from 13% to 11% (*P*-trend = 0.01), but energy intake has increased over this period, suggesting similar exposure to absolute amounts of saturated fat over time [13]. Average trans fat intake in the United States during the enrollment period for this study was approximately 2% to 3% of energy, which is greater than reported by participants of this study [14]. Despite a large body of evidence that alcohol increases risk of breast cancer [15], there was no association between alcohol intake and breast cancer survival. Others have recently reported either no association between alcohol intake and survival or an inverse relation between alcohol intake and survival, so this area warrants further study [16-18].

Similar to our findings, qualitative reviews reported no consistent association between total fat consumption either pre- or post-diagnosis and breast cancer survival after energy adjustment [19,20]. None of the studies reviewed by Rock and Demark-Wahnefried reported an association between total dietary fiber intake and breast cancer recurrence or overall survival; only three studies reported an inverse association between fruit and vegetable consumption and survival [21].

Strengths of our study include the prospective design, its large sample size, and detailed information on diet obtained after the diagnosis of breast cancer. In addition, we were able to assess many potential confounding variables. The relation between saturated and trans fat intake and all-cause survival that we observed is consistent with observational and controlled-feeding studies of cardiovascular disease and other chronic diseases [22-24]. This also supports the ability of our dietary assessment to detect moderate associations with survival.

When restricting attention to deaths related to cardiovascular disease (N = 123), there were suggestive (P-trend = 0.11) inverse associations between trans fat and survival, and positive associations between polyunsaturated fat (P-trend = 0.05) as well as alcohol (P-trend =

0.14) with survival, although these associations likely did not reach statistical significance, possibly because of the limited number of observed deaths.

Nonetheless, some limitations should be considered when interpreting these results. Though we used a validated self-reported measure of diet adapted from the Nurses' Health Study (NHS), measurement error is a pervasive problem in dietary assessment [25-27]. Because measurement error is likely non-differential with respect to outcome, this should lead to attenuation in risk estimates. We lacked information on the clinical status of breast cancer at the time of the CWLS questionnaire, but we excluded women who reported any recurrence of breast cancer at that time. Also, survival may depend upon hormone responsiveness [28], but steroid receptor status was not available from state cancer registries for all CWLS participants.

The CWLS involved women that were previously enrolled in our sequential case-control studies of breast cancer, and thus women were not immediately followed from the initial diagnosis of their breast cancer. One practical limitation of the data is that our results may only be applicable to women who survive the first several years after breast cancer diagnosis. A potential concern is that the observed inverse associations with survival might reflect reverse causation if increased saturated and trans fat intakes are associated with worsening health and poor prognosis. The relatively short interval, however, between diagnosis and subsequent entry into the cohort for the majority of women minimizes the likelihood of bias caused by selective survival. Also, information was available on a number of surrogate measures including treatment interfering with diet, recent unintentional weight loss, general health status, and frequency of mammogram or physician breast or chest wall examination after diagnosis, and hazard ratios were essentially unchanged in analyses restricted to women in apparent good health at the time of CWLS entry and who had undergone screening since diagnosis. Taken together, these results suggest that reverse causation is unlikely to account for the inverse association of saturated and trans fat intake with overall survival in these data.

Finally, our study did not consider diet prior to breast cancer diagnosis, or the pre- to post-diagnosis change in dietary patterns. Our study, instead, was designed to inform how a woman's post-diagnosis diet influences survival. This research provides little evidence for an association between dietary intake and breast cancer survival, but provides additional support for an adverse relationship between saturated and trans fat intake and overall survival following a breast cancer diagnosis.

### **ACKNOWLEDGEMENTS**

This research was supported by grants from the Susan G. Komen Breast Cancer Foundation (POP0504234) and the National Cancer Institute, National Institutes of Health, and Department of Health and Human Services (CA47147, CA47305, CA69664, and CA94880).

Table 1. CWLS participant characteristics

N(%)         All-cause Deaths, % N = 525         Breast cancer Deaths, % N = 525         Deaths, % N = 137           Characteristics at breast cancer diagnosis           Age, y         <40         172 (3.9%)         1.5%         5.8%           40-49         686 (15.4%)         7.4%         18.3%           50-59         1.377 (31.0%)         17.9%         34.3%           60-69         1,669 (37.6%)         40.2%         35.8%           70-79         537 (12.1%)         33.0%         5.8%           Breast cancer stage         Local         3,233 (72.8%)         10.3%         1.8%           Regional         1,208 (27.2%)         16.0%         6.6%           Postmenopausal <sup>b</sup> No         1,011 (22.8%)         4.9%         3.5%           Yes         3,254 (73.3%)         14.4%         3.0%           Alcohol, drinks/d         None         702 (15.8%)         13.8%         3.0%           <1         2,946 (66.3%)         11.2%         3.0%           <1         2,946 (66.3%)         11.2%         3.0%           <2         239 (54.4%)         14.2%         4.6%           Hormone replacement therapy, duration         None         2,527 (56.9%)         11.9%		11(0()			
N = 4,441a         N = 525         N = 137           Characteristics at breast cancer diagnosis           Age, y         40         172 (3.9%)         1.5%         5.8%           40-49         686 (15.4%)         7.4%         18.3%           50-59         1,377 (31.0%)         17.9%         34.3%           60-69         1,669 (37.6%)         40.2%         35.8%           70-79         537 (12.1%)         33.0%         5.8%           Breast cancer stage         Local         3,233 (72.8%)         10.3%         1.8%           Regional         1,208 (27.2%)         16.0%         6.6%           Postmenopausalb         1         6.6%         16.0%         6.6%           Postmenopausalb         1         1.011 (22.8%)         4.9%         3.5%         18.5%         2.8%         18.5%         2.8%         18.5%		N (%)			
Characteristics at breast cancer diagnosis         Age, y       <40		$N = 4.441^{a}$	· · · · · · · · · · · · · · · · · · ·	-	
Age, y       <40	Characteristics at breast	•			
<40		cancer diagnosis			
40-49 686 (15.4%) 7.4% 18.3% 50-59 1,377 (31.0%) 17.9% 34.3% 60-69 1,669 (37.6%) 40.2% 35.8% 70-79 537 (12.1%) 33.0% 5.8%  Breast cancer stage  Local 3,233 (72.8%) 10.3% 1.8% Regional 1,208 (27.2%) 16.0% 6.6%  Postmenopausal <sup>b</sup> No 1,011 (22.8%) 4.9% 3.5% Yes 3,254 (73.3%) 14.4% 3.0%  Alcohol, drinks/d  None 702 (15.8%) 13.8% 3.0% <1 2,946 (66.3%) 11.2% 3.0%  1-2 530 (11.9%) 11.7% 2.8% ≥2 239 (5.4%) 14.2% 4.6%  Hormone replacement therapy, duration  None 2,527 (56.9%) 11.9% 3.0% <2 years 357 (8.0%) 14.9% 3.6% ≥2 years 1,120 (25.2%) 9.0% 3.2%  Smoking history  Never 2,136 (48.1%) 9.2% 2.8% Former 1,536 (34.6%) 13.1% 2.8%  Current 752 (16.9%) 17.0% 4.5%  Education <12 years 388 (8.7%) 18.6% 2.6% ≥12 years 388 (8.7%) 18.6% 2.6% ≥12 years 4,041 (91.0%) 11.5% 3.1%  Breast cancer treatment <sup>c</sup> Surgery 4,346 (97.9%) 11.5% 3.1% Radiation 2,210 (49.8%) 9.7% 3.5% Hormonal therapy 2,568 (57.8%) 10.9% 3.4%	-	172 (3.9%)	1.5%	5.8%	
50-59 1,377 (31.0%) 17.9% 34.3% 60-69 1,669 (37.6%) 40.2% 35.8% 70-79 537 (12.1%) 33.0% 5.8% Breast cancer stage  Local 3,233 (72.8%) 10.3% 1.8% Regional 1,208 (27.2%) 16.0% 6.6% Postmenopausal <sup>b</sup> No 1,011 (22.8%) 4.9% 3.5% Yes 3,254 (73.3%) 14.4% 3.0% Alcohol, drinks/d  None 702 (15.8%) 13.8% 3.0% <1 2,946 (66.3%) 11.2% 3.0% 1-2 530 (11.9%) 11.7% 2.8% >2 239 (5.4%) 14.2% 4.6% Hormone replacement therapy, duration  None 2,527 (56.9%) 11.9% 3.0% <2 years 357 (8.0%) 14.9% 3.6% ≥2 years 1,120 (25.2%) 9.0% 3.2% Smoking history  Never 2,136 (48.1%) 9.2% 2.8% Former 1,536 (34.6%) 13.1% 2.8% Current 752 (16.9%) 17.0% 4.5% Education <12 years 388 (8.7%) 18.6% 2.6% ≥12 years 4,041 (91.0%) 11.2% 3.1% Breast cancer treatment Surgery 4,346 (97.9%) 11.5% 3.1% Radiation 2,210 (49.8%) 9.7% 3.5% Hormonal therapy 2,568 (57.8%) 10.9% 3.4%		•			
60-69 1,669 (37.6%) 40.2% 35.8% 70-79 537 (12.1%) 33.0% 5.8% Breast cancer stage  Local 3,233 (72.8%) 10.3% 1.8% Regional 1,208 (27.2%) 16.0% 6.6% Postmenopausal <sup>b</sup> No 1,011 (22.8%) 4.9% 3.5% Yes 3,254 (73.3%) 14.4% 3.0% Alcohol, drinks/d  None 702 (15.8%) 13.8% 3.0% <1 2,946 (66.3%) 11.2% 3.0% 1-2 530 (11.9%) 11.7% 2.8% ≥2 239 (5.4%) 14.2% 4.6% Hormone replacement therapy, duration  None 2,527 (56.9%) 11.9% 3.0% 3.6% ≥2 years 357 (8.0%) 14.9% 3.6% ≥2 years 1,120 (25.2%) 9.0% 3.2% Smoking history  Never 2,136 (48.1%) 9.2% 2.8% Former 1,536 (34.6%) 13.1% 2.8% Current 752 (16.9%) 17.0% 4.5% Education <12 years 388 (8.7%) 18.6% 2.6% ≥12 years 388 (8.7%) 18.6% 2.6% ≥12 years 4,041 (91.0%) 11.2% 3.1% Breast cancer treatment Surgery 4,346 (97.9%) 11.5% 3.1% Radiation 2,210 (49.8%) 9.7% 3.5% Hormonal therapy 2,568 (57.8%) 10.9% 3.4%					
70-79       537 (12.1%)       33.0%       5.8%         Breast cancer stage       Local       3,233 (72.8%)       10.3%       1.8%         Regional       1,208 (27.2%)       16.0%       6.6%         Postmenopausal <sup>b</sup>		•			
Breast cancer stage  Local 3,233 (72.8%) 10.3% 1.8% Regional 1,208 (27.2%) 16.0% 6.6%  Postmenopausal <sup>b</sup> No 1,011 (22.8%) 4.9% 3.5% Yes 3,254 (73.3%) 14.4% 3.0%  Alcohol, drinks/d  None 702 (15.8%) 13.8% 3.0% <1 2,946 (66.3%) 11.2% 3.0%  1-2 530 (11.9%) 11.7% 2.8%  2.8%  22 (239 (5.4%)) 14.2% 4.6%  Hormone replacement therapy, duration  None 2,527 (56.9%) 11.9% 3.0%  3.6%  22 years 357 (8.0%) 14.9% 3.6%  3.2%  3.3%		· · · · · · · · · · · · · · · · · · ·			
Local 3,233 (72.8%) 10.3% 1.8% Regional 1,208 (27.2%) 16.0% 6.6%  Postmenopausal <sup>b</sup> No 1,011 (22.8%) 4.9% 3.5% Yes 3,254 (73.3%) 14.4% 3.0%  Alcohol, drinks/d  None 702 (15.8%) 13.8% 3.0% <1 2,946 (66.3%) 11.2% 3.0%  1-2 530 (11.9%) 11.7% 2.8% ≥2 239 (5.4%) 14.2% 4.6%  Hormone replacement therapy, duration  None 2,527 (56.9%) 11.9% 3.0% <2 years 357 (8.0%) 14.9% 3.6% ≥2 years 1,120 (25.2%) 9.0% 3.2%  Smoking history  Never 2,136 (48.1%) 9.2% 2.8%  Former 1,536 (34.6%) 13.1% 2.8%  Current 752 (16.9%) 11.0% 4.5%  Education <12 years 388 (8.7%) 18.6% 2.6% ≥12 years 4,041 (91.0%) 11.2% 3.1%  Breast cancer treatment <sup>c</sup> Surgery 4,346 (97.9%) 11.5% 3.1%  Radiation 2,210 (49.8%) 9.7% 3.5%  Hormonal therapy 2,568 (57.8%) 10.9% 3.4%		(,,,)	00.070	0.070	
Regional       1,208 (27.2%)       16.0%       6.6%         Postmenopausal <sup>b</sup> No       1,011 (22.8%)       4.9%       3.5%         Yes       3,254 (73.3%)       14.4%       3.0%         Alcohol, drinks/d       TO2 (15.8%)       13.8%       3.0%         None       702 (15.8%)       13.8%       3.0%         <1		3.233 (72.8%)	10.3%	1.8%	
Postmenopausalb         No       1,011 (22.8%)       4.9%       3.5%         Yes       3,254 (73.3%)       14.4%       3.0%         Alcohol, drinks/d       None       702 (15.8%)       13.8%       3.0%         <1		· · · · · · · · · · · · · · · · · · ·			
No       1,011 (22.8%)       4.9%       3.5%         Yes       3,254 (73.3%)       14.4%       3.0%         Alcohol, drinks/d       None       702 (15.8%)       13.8%       3.0%         <1		, (			
Yes       3,254 (73.3%)       14.4%       3.0%         Alcohol, drinks/d       None       702 (15.8%)       13.8%       3.0%         <1	•	1,011 (22.8%)	4.9%	3.5%	
Alcohol, drinks/d       None       702 (15.8%)       13.8%       3.0%         <1	Yes	,		3.0%	
None 702 (15.8%) 13.8% 3.0% <1 2,946 (66.3%) 11.2% 3.0% 1-2 530 (11.9%) 11.7% 2.8% >2 239 (5.4%) 14.2% 4.6% Hormone replacement therapy, duration None 2,527 (56.9%) 11.9% 3.0% <2 years 357 (8.0%) 14.9% 3.6% ≥2 years 1,120 (25.2%) 9.0% 3.2% Smoking history Never 2,136 (48.1%) 9.2% 2.8% Former 1,536 (34.6%) 13.1% 2.8% Current 752 (16.9%) 17.0% 4.5% Education <12 years 388 (8.7%) 18.6% 2.6% ≥ 12 years 388 (8.7%) 18.6% 2.6% 2.12 years 4,041 (91.0%) 11.2% 3.1% Breast cancer treatment $^{c}$ Surgery 4,346 (97.9%) 11.5% 3.1% Radiation 2,210 (49.8%) 9.7% 3.5% Hormonal therapy 2,568 (57.8%) 10.9% 3.4%	Alcohol, drinks/d	, , ,			
<1		702 (15.8%)	13.8%	3.0%	
1-2 530 (11.9%) 11.7% 2.8%  >2 239 (5.4%) 14.2% 4.6%  Hormone replacement therapy, duration  None 2,527 (56.9%) 11.9% 3.0%  <2 years 357 (8.0%) 14.9% 3.6%  ≥2 years 1,120 (25.2%) 9.0% 3.2%  Smoking history  Never 2,136 (48.1%) 9.2% 2.8%  Former 1,536 (34.6%) 13.1% 2.8%  Current 752 (16.9%) 17.0% 4.5%  Education  <12 years 388 (8.7%) 18.6% 2.6%  ≥ 12 years 4,041 (91.0%) 11.2% 3.1%  Breast cancer treatment°  Surgery 4,346 (97.9%) 11.5% 3.1%  Radiation 2,210 (49.8%) 9.7% 3.5%  Hormonal therapy 2,568 (57.8%) 10.9% 3.4%	<1		11.2%	3.0%	
Hormone replacement therapy, duration         None       2,527 (56.9%)       11.9%       3.0%         <2 years	1-2	· · · · · · · · · · · · · · · · · · ·	11.7%	2.8%	
None       2,527 (56.9%)       11.9%       3.0%         <2 years	>2	239 (5.4%)	14.2%	4.6%	
<2 years	Hormone replacement the	rapy, duration			
≥2 years 1,120 (25.2%) 9.0% 3.2%  Smoking history  Never 2,136 (48.1%) 9.2% 2.8%  Former 1,536 (34.6%) 13.1% 2.8%  Current 752 (16.9%) 17.0% 4.5%  Education  < 12 years 388 (8.7%) 18.6% 2.6%  ≥ 12 years 4,041 (91.0%) 11.2% 3.1%  Breast cancer treatment <sup>c</sup> Surgery 4,346 (97.9%) 11.5% 3.1%  Radiation 2,210 (49.8%) 9.7% 3.5%  Hormonal therapy 2,568 (57.8%) 10.9% 3.4%	-	• •	11.9%	3.0%	
Smoking history       2,136 (48.1%)       9.2%       2.8%         Former       1,536 (34.6%)       13.1%       2.8%         Current       752 (16.9%)       17.0%       4.5%         Education       4.2 years       388 (8.7%)       18.6%       2.6%         ≥ 12 years       4,041 (91.0%)       11.2%       3.1%         Breast cancer treatment <sup>c</sup> 3.1%       3.1%         Surgery       4,346 (97.9%)       11.5%       3.1%         Radiation       2,210 (49.8%)       9.7%       3.5%         Hormonal therapy       2,568 (57.8%)       10.9%       3.4%	<2 years	357 (8.0%)	14.9%	3.6%	
Never       2,136 (48.1%)       9.2%       2.8%         Former       1,536 (34.6%)       13.1%       2.8%         Current       752 (16.9%)       17.0%       4.5%         Education       388 (8.7%)       18.6%       2.6%         ≥ 12 years       4,041 (91.0%)       11.2%       3.1%         Breast cancer treatment <sup>c</sup> Surgery       4,346 (97.9%)       11.5%       3.1%         Radiation       2,210 (49.8%)       9.7%       3.5%         Hormonal therapy       2,568 (57.8%)       10.9%       3.4%	≥2 years	1,120 (25.2%)	9.0%	3.2%	
Former 1,536 (34.6%) 13.1% 2.8% Current 752 (16.9%) 17.0% 4.5% Education < 12 years 388 (8.7%) 18.6% 2.6% ≥ 12 years 4,041 (91.0%) 11.2% 3.1% Breast cancer treatment Surgery 4,346 (97.9%) 11.5% 3.1% Radiation 2,210 (49.8%) 9.7% 3.5% Hormonal therapy 2,568 (57.8%) 10.9% 3.4%	Smoking history				
Current       752 (16.9%)       17.0%       4.5%         Education       388 (8.7%)       18.6%       2.6%         ≥ 12 years       4,041 (91.0%)       11.2%       3.1%         Breast cancer treatment <sup>c</sup> Surgery       4,346 (97.9%)       11.5%       3.1%         Radiation       2,210 (49.8%)       9.7%       3.5%         Hormonal therapy       2,568 (57.8%)       10.9%       3.4%	Never	2,136 (48.1%)	9.2%	2.8%	
Education < 12 years ≥ 12 years 4,041 (91.0%) Breast cancer treatment <sup>c</sup> Surgery Radiation 4,346 (97.9%) 4,346 (97.9%) 11.5% 3.1% Radiation 2,210 (49.8%) 9.7% 3.5% Hormonal therapy 2,568 (57.8%) 10.9% 3.4%	Former	1,536 (34.6%)	13.1%	2.8%	
< 12 years 388 (8.7%) ≥ 12 years 4,041 (91.0%) 11.2% 3.1% Breast cancer treatment° Surgery 4,346 (97.9%) 11.5% 3.1% Radiation 2,210 (49.8%) 9.7% 3.5% Hormonal therapy 2,568 (57.8%) 10.9% 3.4%	Current	752 (16.9%)	17.0%	4.5%	
≥ 12 years 4,041 (91.0%) 11.2% 3.1%  Breast cancer treatment <sup>c</sup> Surgery 4,346 (97.9%) 11.5% 3.1%  Radiation 2,210 (49.8%) 9.7% 3.5%  Hormonal therapy 2,568 (57.8%) 10.9% 3.4%	Education				
Breast cancer treatment <sup>c</sup> 4,346 (97.9%)       11.5%       3.1%         Surgery       4,346 (97.9%)       9.7%       3.5%         Radiation       2,210 (49.8%)       9.7%       3.5%         Hormonal therapy       2,568 (57.8%)       10.9%       3.4%	< 12 years	388 (8.7%)	18.6%	2.6%	
Surgery       4,346 (97.9%)       11.5%       3.1%         Radiation       2,210 (49.8%)       9.7%       3.5%         Hormonal therapy       2,568 (57.8%)       10.9%       3.4%	≥ 12 years	4,041 (91.0%)	11.2%	3.1%	
Radiation       2,210 (49.8%)       9.7%       3.5%         Hormonal therapy       2,568 (57.8%)       10.9%       3.4%	Breast cancer treatment <sup>c</sup>				
Hormonal therapy 2,568 (57.8%) 10.9% 3.4%	Surgery	4,346 (97.9%)	11.5%	3.1%	
	Radiation	2,210 (49.8%)	9.7%	3.5%	
Chemotherapy 1,417 (31.9%) 9.7% 5.3%	Hormonal therapy	2,568 (57.8%)	10.9%	3.4%	
	Chemotherapy	1,417 (31.9%)	9.7%	5.3%	
Characteristics at follow-up	Characteristics at follow-	-up			
Body mass index, kg/m <sup>2</sup>	_	-			
<20 209 (4.7%) 19.6% 1.9%		209 (4.7%)	19.6%	1.9%	
20-24.9 1,485 (33.4%) 10.2% 2.2%	20-24.9	1,485 (33.4%)	10.2%	2.2%	
25-29.9 1,452 (32.7%) 10.7% 2.8%	25-29.9	1,452 (32.7%)	10.7%	2.8%	

≥30	1,038 (23.4%)	12.9%	4.9%
Physical activity, MET-h/v	wk		
<u>≤</u> 2.7	1,064 (24.0%)	20.4%	4.0%
2.8-7.9	1,038 (23.4%)	10.2%	2.6%
8.0-20.9	1,147 (25.8%)	8.8%	2.8%
<u>&gt;</u> 21.0	1,091 (24.6%)	7.2%	3.0%

a Numbers may not sum to total because of missing values
b Women with unknown menopausal status are excluded
c Can reflect more than one treatment type

Table 2. Association of total energy and macronutrient intake with all-cause (N = 525) and breast cancer (N = 137) survival,  $^{15}_{CWLS}$ 

	Macronutrient intake (quintiles)					
	1	2	3	4	5	<i>P</i> -trend
Total energy (kcal) <sup>a</sup>	1,077	1,400	1,649	1,935	2,407	_
All-cause survival HR (95% CI) <sup>b</sup>	Ref	0.78 (0.60-1.02)	0.86 (0.66-1.11)	0.78 (0.59-1.02)	0.89 (0.68-1.15)	0.33
Breast cancer survival HR (95% CI) <sup>b</sup>	Ref	0.91 (0.53-1.57)	0.89 (0.51-1.54)	0.94 (0.55-1.60)	1.02 (0.61-1.71)	0.89
Total fat (% kcal) <sup>a</sup>	23	27	30	34	39	
All-cause survival HR (95% CI) <sup>b</sup>	Ref	1.11 (0.84-1.47)	1.00 (0.76-1.33)	1.02 (0.78-1.35)	1.05 (0.79-1.39)	0.98
Breast cancer survival HR (95% CI) <sup>b</sup>	Ref	1.11 (0.65-1.91)	1.00 (0.58-1.73)	0.76 (0.43-1.35)	0.92 (0.53-1.60)	0.39
Saturated fat (% kcal) <sup>a</sup>	7	8	10	11	13	
All-cause survival HR (95% CI) <sup>b</sup>	Ref	1.06 (0.79-1.41)	1.25 (0.94-1.65)	1.05 (0.78-1.40)	1.41 (1.06-1.87)	0.03
Breast cancer survival HR (95% CI) <sup>b</sup>	Ref	1.56 (0.88-2.74)	1.32 (0.74-2.37)	1.01 (0.55-1.87)	1.55 (0.88-2.75)	0.50
Trans fat (% kcal) <sup>a</sup>	0.7	0.9	1.1	1.3	1.6	
All-cause survival HR (95% CI) <sup>b</sup>	Ref	1.10 (0.82-1.49)	1.14 (0.85-1.53)	1.21 (0.90-1.62)	1.78 (1.35-2.32)	0.01
Breast cancer survival HR (95% CI) <sup>b</sup>	Ref	1.27 (0.72-2.23)	1.25 (0.71-2.18)	1.19 (0.66-2.13)	1.42 (0.80-2.52)	0.34
Monounsaturated fat (% kcal) <sup>a</sup>	8	10	11	13	15	
All-cause survival HR (95% CI) <sup>b</sup>	Ref	1.27 (0.97-1.68)	1.27 (0.96-1.67)	0.95 (0.71-1.28)	1.14 (0.86-1.52)	0.93
Breast cancer survival HR (95% CI) <sup>b</sup>	Ref	1.58 (0.93-2.71)	1.10 (0.62-1.94)	1.06 (0.59-1.89)	0.89 (0.49-1.60)	0.25
Polyunsaturated fat (% kcal) <sup>a</sup>	4	5	5	6	8	
All-cause survival HR (95% CI) <sup>b</sup>	Ref	1.00 (0.77-1.32)	0.81 (0.61-1.07)	0.93 (0.71-1.22)	0.91 (0.70-1.19)	0.41
Breast cancer survival HR (95% CI) <sup>b</sup>	Ref	1.28 (0.76-2.17)	1.00 (0.58-1.73)	0.89 (0.51-1.57)	0.90 (0.52-1.55)	0.33
Carbohydrates (% kcal) <sup>a</sup>	42	49	53	57	63	
All-cause survival HR (95% CI) <sup>b</sup>	Ref	1.07 (0.80-1.41)	1.00 (0.75-1.33)	1.06 (0.79-1.42)	0.97 (0.72-1.30)	0.80
Breast cancer survival HR (95% CI) <sup>b</sup>	Ref	0.81 (0.47-1.37)	0.80 (0.47-1.35)	1.08 (0.64-1.81)	0.93 (0.54-1.62)	0.87
Protein (% kcal) <sup>a</sup>	13	16	17	18	21	
All-cause survival HR (95% CI) <sup>b</sup>	Ref	0.93 (0.72-1.20)	0.89 (0.68-1.16)	1.09 (0.84-1.42)	0.98 (0.73-1.31)	0.72
Breast cancer survival HR (95% CI) <sup>b</sup>	Ref	1.37 (0.77-2.42)	1.36 (0.77-2.42)	1.60 (0.91-2.80)	1.19 (0.66-2.14)	0.49
Alcohol (% kcal) <sup>a</sup>	0.0	0.3	1.2	4.9	15.0	
All-cause survival HR (95% CI) <sup>b</sup>	Ref	0.99 (0.77-1.27)	0.83 (0.65-1.07)	0.68 (0.51-0.90)	0.78 (0.60-1.01)	0.01
Breast cancer survival HR (95% CI) <sup>b</sup>	Ref	0.88 (0.50-1.55)	1.21 (0.74-2.01)	0.81 (0.46-1.44)	1.27 (0.76-2.14)	0.50

<sup>&</sup>lt;sup>a</sup> Median within each quintile.

<sup>&</sup>lt;sup>b</sup> Hazard ratio (95% confidence interval) adjusted for factors at diagnosis (age, state of residence, menopausal status, smoking, breast cancer stage, alcohol, history of hormone replacement therapy), interval between diagnosis and diet assessment, and factors at follow-up (energy intake, breast cancer treatment, body mass index, and physical activity).

Table 3. Association of micronutrient intake with all-cause (N = 525) and breast cancer (N = 137) survival, CWLS

	Micronutrient intake (quintiles)					
	1	2	3	4	5	<b>P</b> -1
<b>Vitamin A</b> (IU/d) <sup>a</sup>	4816	8070	10939	14453	21857	
All-cause survival HR (95% CI) <sup>b</sup>	Ref	0.97 (0.75-1.27)	1.00 (0.76-1.32)	1.05 (0.79-1.40)	1.12 (0.84-1.50)	0
Breast cancer survival HR (95% CI) <sup>b</sup>	Ref	1.40 (0.82-2.40)	1.19 (0.67-2.12)	1.18 (0.66-2.12)	1.24 (0.68-2.24)	0
Carotenoids						
α-Carotene (μg/d) <sup>a</sup>	206	406	582	864	1752	
All-cause survival HR (95% CI) <sup>b</sup>	Ref	1.10 (0.85-1.42)	0.97 (0.74-1.29)	0.94 (0.70-1.27)	1.08 (0.81-1.43)	0
Breast cancer survival HR (95% CI) <sup>b</sup>	Ref	0.93 (0.57-1.50)	0.63 (0.36-1.09)	0.54 (0.30-0.99)	0.98 (0.59-1.64)	0
β-Carotene (μg/d) <sup>a</sup>	1610	2549	3644	5156	8570	
All-cause survival HR (95% CI) <sup>b</sup>	Ref	0.98 (0.75-1.28)	1.25 (0.95-1.64)	1.05 (0.79-1.40)	1.17 (0.88-1.57)	0
Breast cancer survival HR (95% CI) <sup>b</sup>	Ref	1.06 (0.63-1.81)	1.00 (0.58-1.73)	0.93 (0.52-1.65)	1.05 (0.60-1.86)	0
β-Cryptoxanthin (μg/d) <sup>a</sup>	45	99	170	228	329	
All-cause survival HR (95% CI) <sup>b</sup>	Ref	1.06 (0.79-1.41)	1.18 (0.89-1.56)	1.18 (0.89-1.57)	1.25 (0.93-1.68)	0
Breast cancer survival HR (95% CI) <sup>b</sup>	Ref	0.56 (0.32-1.00)	1.22 (0.75-1.99)	0.77 (0.44-1.34)	0.81 (0.45-1.45)	0
Lutein/Zeaxanthin (µg/d) <sup>a</sup>	995	1543	2174	2950	4591	
All-cause survival HR (95% CI) <sup>b</sup>	Ref	0.99 (0.75-1.30)	0.98 (0.74-1.29)	1.31 (0.99-1.74)	1.05 (0.77-1.43)	0
Breast cancer survival HR (95% CI) <sup>b</sup>	Ref	1.25 (0.71-2.21)	0.99 (0.54-1.81)	1.38 (0.78-2.46)	1.16 (0.62-2.19)	0
Lycopene (µg/d) <sup>a</sup>	2102	3908	4734	6222	11479	
All-cause survival HR (95% CI) <sup>b</sup>	Ref	0.93 (0.72-1.21)	1.08 (0.83-1.41)	0.98 (0.73-1.31)	1.11 (0.83-1.47)	0
Breast cancer survival HR (95% CI) <sup>b</sup>	Ref	0.72 (0.39-1.34)	1.08 (0.61-1.91)	0.89 (0.49-1.63)	1.42 (0.80-2.50)	0
Fiber (g/d) <sup>a</sup>	11	15	19	23	30	
All-cause survival HR (95% CI) <sup>b</sup>	Ref	1.00 (0.77-1.32)	0.79 (0.58-1.08)	0.96 (0.69-1.32)	0.75 (0.52-1.09)	0
Breast cancer survival HR (95% CI) <sup>b</sup>	Ref	0.92 (0.55-1.56)	0.65 (0.35-1.18)	0.62 (0.33-1.17)	0.75 (0.38-1.49)	0
Whole grains (g/d)	7	16	26	37	57	

All-cause survival HR (95% CI) <sup>b</sup>	Ref	1.03 (0.79-1.33)	1.05 (0.80-1.37)	0.98 (0.74-1.30)	0.79 (0.59-1.08)	0
Breast cancer survival HR (95% CI) <sup>b</sup>	Ref	0.96 (0.58-1.60)	1.16 (0.70-1.92)	0.66 (0.37-1.20)	0.83 (0.46-1.48)	0
Calcium (mg/d) <sup>a</sup>	622	947	1302	1735	4108	
All-cause survival HR (95% CI) <sup>b</sup>	Ref	0.81 (0.62-1.05)	0.98 (0.75-1.28)	0.96 (0.73-1.27)	0.74 (0.53-1.02)	0
Breast cancer survival HR (95% CI) <sup>b</sup>	Ref	0.80 (0.48-1.34)	0.84 (0.50-1.44)	0.70 (0.40-1.23)	0.59 (0.32-1.08)	0
<b>Vitamin D</b> (mg/d) <sup>a</sup>	81	190	438	558	826	
All-cause survival HR (95% CI) <sup>b</sup>	Ref	1.02 (0.79-1.32)	0.87 (0.66-1.14)	1.00 (0.77-1.33)	0.86 (0.64-1.16)	0
Breast cancer survival HR (95% CI) <sup>b</sup>	Ref	1.03 (0.60-1.76)	0.96 (0.55-1.66)	1.08 (0.63-1.86)	1.02 (0.58-1.79)	0

<sup>&</sup>lt;sup>a</sup> Median intake within each quintile. Includes intake from diet and supplements.

<sup>b</sup> Hazard ratio (95% confidence interval) adjusted for factors at diagnosis (age, state of residence, menopausal status, smoking, breast cancer stage, alcohol, history of hormone replacement therapy), interval between diagnosis and diet assessment, and factors at follow-up (energy intake, breast catreatment, body mass index, and physical activity).

Table 4. Associations of selected food group intake with all-cause (N = 525) and breast cancer (N = 137) survival, **CWLS** 

		Food grou	up intake (quartiles)		<i>P</i> -trend
	1	2	3	4	
Dairy (servings/d) <sup>a</sup>	0.7	1.5	2.6	4.0	-
All-cause survival HR (95% CI) <sup>b</sup>	Ref	0.92 (0.72-1.17)	0.95 (0.74-1.23)	1.18 (0.90-1.54)	0.27
Breast cancer survival HR (95% CI) <sup>b</sup>	Ref	0.76 (0.46-1.27)	0.94 (0.58-1.53)	0.94 (0.56-1.59)	0.99
Meat (servings/d) <sup>a</sup>	0.7	1.1	1.5	2.2	
All-cause survival HR (95% CI) <sup>b</sup>	Ref	1.12 (0.88-1.43)	1.11 (0.85-1.44)	1.12 (0.83-1.51)	0.46
Breast cancer survival HR (95% CI) <sup>b</sup>	Ref	0.89 (0.53-1.52)	1.20 (0.71-2.01)	0.89 (0.50-1.60)	0.94
Vegetables (servings/d) <sup>a</sup> All-cause survival HR (95% CI) <sup>b</sup>	0.4 Ref	0.8 1.04 (0.83-1.31)	1.0 1.04 (0.84-1.30)	2.5 1.44 (0.91-2.27)	0.35
Breast cancer survival HR (95% CI) <sup>b</sup>	Ref	1.00 (0.65-1.56)	0.82 (0.54-1.25)	0.96 (0.38-2.45)	0.43
Cruciferous vegetables (servings/d) <sup>a</sup> All-cause survival HR (95% CI) <sup>b</sup>	0.1 Ref	0.2 0.77 (0.61-0.98)	0.3 1.11 (0.87-1.43)	0.7 1.02 (0.80-1.30)	0.35
Breast cancer survival HR (95% CI) <sup>b</sup>	Ref	0.83 (0.51-1.35)	1.15 (0.70-1.90)	0.95 (0.59-1.54)	0.86
Fruit (servings/d) <sup>a</sup>	0.1	0.4	1.0	2.5	
All-cause survival HR (95% CI) <sup>b</sup>	Ref	0.83 (0.62-1.11)	0.89 (0.73-1.09)	1.38 (0.88-2.17)	0.67
Breast cancer survival HR (95% CI) <sup>b</sup>	Ref	0.65 (0.36-1.19)	0.66 (0.45-0.97)	1.39 (0.64-2.99)	0.16

a Median within each quartile.
b Hazard ratio (95% confidence interval) adjusted for factors at diagnosis (age, state of residence, menopausal status, smoking, breast cancer stage, alcohol, history of hormone replacement therapy), interval between diagnosis and diet assessment, and factors at follow-up (energy intake, breast cancer treatment, body mass index, and physical activity).

### REFERENCES

1. Thiebaut AC, Kipnis V, Chang SC, Subar AF, Thompson FE, Rosenberg PS, Hollenbeck AR, Leitzmann M, Schatzkin A (2007) Dietary fat and postmenopausal invasive breast cancer in the National Institutes of Health-AARP Diet and Health Study cohort. J Natl Cancer Inst 99 (6):451-462. doi:99/6/451 [pii]10.1093/jnci/djk094

2. Chlebowski RT, Blackburn GL, Thomson CA, Nixon DW, Shapiro A, Hoy MK, Goodman MT, Giuliano AE, Karanja N, McAndrew P, Hudis C, Butler J, Merkel D, Kristal A, Caan B, Michaelson R, Vinciguerra V, Del Prete S, Winkler M, Hall R, Simon M, Winters BL, Elashoff RM (2006) Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst 98 (24):1767-1776. doi:98/24/1767 [pii]10.1093/jnci/dji494

3. Pierce JP, Natarajan L, Caan BJ, Parker BA, Greenberg ER, Flatt SW, Rock CL, Kealey S, Al-Delaimy WK, Bardwell WA, Carlson RW, Emond JA, Faerber S, Gold EB, Hajek RA, Hollenbach K, Jones LA, Karanja N, Madlensky L, Marshall J, Newman VA, Ritenbaugh C, Thomson CA, Wasserman L, Stefanick ML (2007) Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial. JAMA 298 (3):289-298. doi:298/3/289 [pii]10.1001/jama.298.3.289

4. Kwan ML, Weltzien E, Kushi LH, Castillo A, Slattery ML, Caan BJ (2009) Dietary patterns and breast cancer recurrence and survival among women with early-stage breast cancer. J Clin Oncol 27 (6):919-926. doi:JCO.2008.19.4035 [pii]10.1200/JCO.2008.19.4035

5. McTiernan A, Irwin M, Vongruenigen V (2010) Weight, physical activity, diet, and prognosis in breast and gynecologic cancers. J Clin Oncol 28 (26):4074-4080. doi:JCO.2010.27.9752 [pii]10.1200/JCO.2010.27.9752

6. Nelson N (2008) Dietary intervention trial reports no effect on survival after breast cancer. J Natl Cancer Inst 100 (6):386-387. doi:djn069 [pii]10.1093/jnci/djn069

7. Holick CN, Newcomb PA, Trentham-Dietz A, Titus-Ernstoff L, Bersch AJ, Stampfer MJ, Baron JA, Egan KM, Willett WC (2008) Physical activity and survival after diagnosis of invasive breast cancer. Cancer Epidemiol Biomarkers Prev 17 (2):379-386. doi:1055-9965.EPI-07-0771 [pii]10.1158/1055-9965.EPI-07-0771

8. Titus-Ernstoff L, Longnecker MP, Newcomb PA, Dain B, Greenberg ER, Mittendorf R, Stampfer M, Willett W (1998) Menstrual factors in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev 7 (9):783-789

9. Sprague BL, Trentham-Dietz A, Newcomb PA, Titus-Ernstoff L, Hampton JM, Egan KM (2007) Lifetime recreational and occupational physical activity and risk of in situ and invasive breast cancer. Cancer Epidemiol Biomarkers Prev 16 (2):236-243. doi:16/2/236 [pii]10.1158/1055-9965.EPI-06-0713

10. Willett WC, Sampson L, Stampfer MJ, Rosner B, Bain C, Witschi J, Hennekens CH, Speizer FE (1985) Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol 122 (1):51-65

 55 11. Calle EE, Terrell DD (1993) Utility of the National Death Index for ascertainment of mortality 56 among cancer prevention study II participants. Am J Epidemiol 137 (2):235-241

12. Willett W (1998) Nutritional epidemiology. Monographs in epidemiology and biostatistics, vol 30, 2nd edn. Oxford University Press, New York

13. Wright JD, Kennedy-Stephenson J, Wang CY, McDowell MA, Johnson CL (2004) Trends in intake of energy and macronutrients - United States, 1971-2000. CDC Morbidity and Mortality Weekly Report 53(4):80-82

14. Allison DB, Egan SK, Barraj LM, Caughman C, Infante M, Heimbach JT (1999) Estimated intakes of trans fatty and other fatty acids in the US population. J Am Diet Assoc 99 (2):166-174; quiz 175-166. doi:S0002-8223(99)00041-3 [pii]10.1016/S0002-8223(99)00041-3

15. Michels KB, Mohllajee AP, Roset-Bahmanyar E, Beehler GP, Moysich KB (2007) Diet and breast cancer: a review of the prospective observational studies. Cancer 109 (12 Suppl):2712-2749. doi:10.1002/cncr.22654

16. Dal Maso L, Zucchetto A, Talamini R, Serraino D, Stocco CF, Vercelli M, Falcini F, Franceschi S (2008) Effect of obesity and other lifestyle factors on mortality in women with breast cancer. Int J Cancer 123 (9):2188-2194. doi:10.1002/ijc.23747

17. Barnett GC, Shah M, Redman K, Easton DF, Ponder BA, Pharoah PD (2008) Risk factors for the incidence of breast cancer: do they affect survival from the disease? J Clin Oncol 26 (20):3310-3316. doi:26/20/3310 [pii]10.1200/JCO.2006.10.3168

18. Reding KW, Daling JR, Doody DR, O'Brien CA, Porter PL, Malone KE (2008) Effect of prediagnostic alcohol consumption on survival after breast cancer in young women. Cancer Epidemiol Biomarkers Prev 17 (8):1988-1996. doi:1055-9965.EPI-07-2897 [pii]10.1158/1055-9965.EPI-07-2897

19. Rock CL, Demark-Wahnefried W (2002) Nutrition and survival after the diagnosis of breast cancer: a review of the evidence. J Clin Oncol 20 (15):3302-3316

20. Kellen E, Vansant G, Christiaens MR, Neven P, Van Limbergen E (2009) Lifestyle changes and breast cancer prognosis: a review. Breast Cancer Res Treat 114 (1):13-22. doi:10.1007/s10549-008-9990-8

21. Fink BN, Gaudet MM, Britton JA, Abrahamson PE, Teitelbaum SL, Jacobson J, Bell P, Thomas JA, Kabat GC, Neugut AI, Gammon MD (2006) Fruits, vegetables, and micronutrient intake in relation to breast cancer survival. Breast Cancer Res Treat 98 (2):199-208. doi:10.1007/s10549-005-9150-3

22. Mozaffarian D, Katan MB, Ascherio A, Stampfer MJ, Willett WC (2006) Trans fatty acids and cardiovascular disease. N Engl J Med 354 (15):1601-1613. doi:354/15/1601 [pii]10.1056/NEJMra054035

23. Mozaffarian D, Pischon T, Hankinson SE, Rifai N, Joshipura K, Willett WC, Rimm EB (2004)
Dietary intake of trans fatty acids and systemic inflammation in women. Am J Clin Nutr
79 (4):606-612

106	
107 108 109 110	24. Trichopoulou A, Kouris-Blazos A, Wahlqvist ML, Gnardellis C, Lagiou P, Polychronopoulos E, Vassilakou T, Lipworth L, Trichopoulos D (1995) Diet and overall survival in elderly people. BMJ 311 (7018):1457-1460
111 111 112 113	25. Willett WC, Hu FB (2007) The food frequency questionnaire. Cancer Epidemiol Biomarkers Prev 16 (1):182-183. doi:16/1/182 [pii]10.1158/1055-9965.EPI-06-0843
114 115 116 117	26. Willett WC, Hu FB (2006) Not the time to abandon the food frequency questionnaire: point. Cancer Epidemiol Biomarkers Prev 15 (10):1757-1758. doi:1055-9965.EPI-06-0388 [pii]10.1158/1055-9965.EPI-06-0388
118 119 120 121	27. Kristal AR, Potter JD (2006) Not the time to abandon the food frequency questionnaire: counterpoint. Cancer Epidemiol Biomarkers Prev 15 (10):1759-1760. doi:1055-9965.EPI-06-0727 [pii]10.1158/1055-9965.EPI-06-0727
122 123 124 125	28. Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP (2006) Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295 (14):1658-1667. doi:295/14/1658 [pii]10.1001/jama.295.14.1658
126 127 128	
129 130	
131	
132	
133	
134	
135	
136	
137 138	
139	
140	
141	
142	
143	
144	
145	
146	
147	
148	